1.
Alasalvar C, Bolling BW. Review of nut phytochemicals, fat-soluble bioactives, antioxidant
components and health effects. The British journal of nutrition. 2015;113 Suppl 2:S68-78.
3.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart
Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association.
Circulation. 2019;139(10):e56-e528.
4.
Cardoso R, Blumenthal RS, Kopecky S, Lopez-Jimenez F, Martin SS. How Low to Go With
Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clin Proc. 2019;94(4):660-9.
5.
Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence
for a mitochondrial mechanism. American journal of cardiovascular drugs : drugs, devices,
and other interventions. 2008;8(6):373-418.
6.
Weinberger T, Sicherer S. Current perspectives on tree nut allergy: a review. Journal
of asthma and allergy. 2018;11:41-51.
7.
Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year Risk
Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular
Disease. Jama. 2015;314(2):142-50.
8.
Lee-Bravatti MA, Wang J, Avendano EE, King L, Johnson EJ, Raman G. Almond consumption
and risk factors for CVD: a systematic review and meta-analysis of randomized controlled
trials Advances in Nutrition. 2019, accepted.
9.
Tan SY, Mattes RD. Appetitive, dietary and health effects of almonds consumed with
meals or as snacks: a randomized, controlled trial. Eur J Clin Nutr. 2013;67(11):1205-14.
11.
Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, Robertus K, et al. Economic outcomes
of percutaneous coronary intervention with drug-eluting stents versus bypass surgery
for patients with left main or three-vessel coronary artery disease: one-year results
from the SYNTAX trial. Catheter Cardiovasc Interv. 2012;79(2):198-209.
12.
Caruba T, Katsahian S, Schramm C, Charles Nelson A, Durieux P, Begue D, et al. Treatment
for stable coronary artery disease: a network meta-analysis of cost-effectiveness
studies. PLoS One. 2014;9(6):e98371.
13.
Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H. Costs and outcomes of noncardioembolic
ischemic stroke in a managed care population. Vasc Health Risk Manag. 2010;6:905-13.
14.
Russo CA, Andrews RM. Hospital Stays for Stroke and Other Cerebrovascular Diseases,
2005: Statistical Brief #51. Healthcare Cost and Utilization Project (HCUP) Statistical
Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.
15.
McFarlane PA, Bayoumi AM. Acceptance and rejection: cost-effectiveness and the working
nephrologist. Kidney international. 2004;66(5):1735-41.
16.
National Center for Health S. Health, United States. Health, United States, 2016:
With Chartbook on Long-term Trends in Health. Hyattsville (MD): National Center for
Health Statistics (US); 2017.
17.
Gulliford MC, Bhattarai N, Charlton J, Rudisill C. Cost-effectiveness of a universal
strategy of brief dietary intervention for primary prevention in primary care: population-based
cohort study and Markov model. Cost Eff Resour Alloc. 2014;12(1):4.
18.
Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of Maintaining
Daily Intake of Oat beta-Glucan for Coronary Heart Disease Primary Prevention. Clin
Ther. 2017;39(4):804-18 e3.
19.
Yang W, Gage H, Jackson D, Raats M. The effectiveness and cost-effectiveness of plant
sterol or stanol-enriched functional foods as a primary prevention strategy for people
with cardiovascular disease risk in England: a modeling study. Eur J Health Econ.
2018;19(7):909-22.
20.
Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness
and costs of interventions to lower systolic blood pressure and cholesterol: a global
and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361(9359):717-25.
22.
Pikula A, Beiser AS, Wang J, Himali JJ, Kelly-Hayes M, Kase CS, et al. Lipid and lipoprotein
measurements and the risk of ischemic vascular events: Framingham Study. Neurology.
2015;84(5):472-9.
23.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and
Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation.
2017;135(10):e146-e603.
24.
Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends
in the United States, 2001-2008. JAMA. 2011;305(17):1769-76.
25.
Eisenberg MJ, Filion KB, Azoulay A, Brox AC, Haider S, Pilote L. Outcomes and cost
of coronary artery bypass graft surgery in the United States and Canada. Arch Intern
Med. 2005;165(13):1506-13.
26.
Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, et al. Cost-effectiveness
of percutaneous coronary intervention with drug eluting stents versus bypass surgery
for patients with diabetes mellitus and multivessel coronary artery disease: results
from the FREEDOM trial. Circulation. 2013;127(7):820-31.
27.
Bakhai A, Stone GW, Grines CL, Murphy SA, Githiora L, Berezin RH, et al. Cost-effectiveness
of coronary stenting and abciximab for patients with acute myocardial infarction:
results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower
Late Angioplasty Complications) trial. Circulation. 2003;108(23):2857-63.
28.
Nelson RE, Saltzman GM, Skalabrin EJ, Demaerschalk BM, Majersik JJ. The cost-effectiveness
of telestroke in the treatment of acute ischemic stroke. Neurology. 2011;77(17):1590-8.